Exact Sciences Corp Stock Price, News & Analysis

Exact Sciences (NASDAQ: EXAS) will release its third quarter 2025 financial results after market close on November 3, 2025. Company management will host a webcast and conference call at 5:00 p.m. ET the same day to discuss results and business progress. The live webcast and a replay will be available at www.exactsciences.com. Telephone access is available for domestic and international callers using access code 4437608.

Investors and other interested parties can join the live webcast or listen by phone; a replay will be posted on the company website.

Exact Sciences (NASDAQ: EXAS) announced a modeling study published in JNCI showing Cologuard Plus, a triennial next‑generation mt‑sDNA test, was the only noninvasive option classified as efficient for screening ages 45–75, delivering the most life‑years gained with the fewest colonoscopies.

The study used the validated CRC‑AIM microsimulation and CISNET methodology, incorporated new clinical data, and reported Cologuard Plus sensitivity of 95% for CRC and specificity of 94% in U.S. screening‑age adults.

Findings note annual FIT was near‑efficient; mt‑RNA and blood‑based tests were not efficient at recommended intervals.

Exact Sciences (NASDAQ: EXAS) has partnered with horror film actor Matthew Lillard to promote colorectal cancer screening through their Cologuard® test. The SCREEN campaign aims to reduce fear around colon cancer screening, highlighting Cologuard as a noninvasive, at-home testing option for those 45 and older.

The campaign emphasizes that Cologuard has been used over 20 million times since FDA approval in 2014. When detected early, colon cancer has a 90% survival rate. The test requires no special preparation and can be completed at home, making it a convenient screening option for individuals at average risk of colorectal cancer.

Exact Sciences (NASDAQ: EXAS) has launched Cancerguard™, a groundbreaking multi-cancer early detection (MCED) blood test priced at $689. The test is the first to analyze multiple biomarker classes and can detect over 50 cancer types, including those responsible for 80% of annual U.S. cancer diagnoses.

Key performance metrics include 68% sensitivity across six deadliest cancers, 64% overall sensitivity across broader cancer types, and 97.4% specificity. The test can detect more than a third of Stage I or II cancers. Modeling suggests that over 10 years, using Cancerguard alongside current screening methods could reduce Stage IV diagnoses by 42% and lower cancer mortality by 18%.

Nationwide accessibility will be facilitated through Quest Diagnostics' 7,000 patient access sites, with broader consumer telehealth access starting October 2025.

Exact Sciences (NASDAQ:EXAS), a cancer screening and diagnostic tests provider, announced its participation in two upcoming investor conferences in September 2025. Management will engage in fireside chats at the Wells Fargo Healthcare Conference in Boston on September 3 at 1:30 p.m. ET and the Baird Global Healthcare Conference in New York on September 9 at 10:50 a.m. ET.

Investors can access the webcasts through the investor relations section of Exact Sciences' website.

Exact Sciences (NASDAQ: EXAS) has secured exclusive U.S. rights to Freenome's blood-based colorectal cancer (CRC) screening tests in a significant licensing deal. The agreement includes both current and future versions of the tests, with Freenome recently completing its FDA premarket approval application submission.

The first-version test demonstrated 81% sensitivity for CRC and 14% for advanced precancerous lesions (APL) at 90% specificity in the PREEMPT study. The deal involves $75 million in upfront cash and up to $700 million in milestone payments, plus potential royalties up to 10%. Exact Sciences is also committing $20 million annually for three years in joint R&D and will purchase a $50 million convertible note from Freenome.

Exact Sciences (NASDAQ:EXAS) reported strong Q2 2025 results with record revenue of $811 million, up 16% year-over-year. The company's Screening segment generated $628 million (18% growth) while Precision Oncology contributed $183 million (9% growth).

Key developments include an exclusive license agreement with Freenome for blood-based colorectal cancer screening tests, Medicare coverage for Oncodetect™, and a productivity plan targeting $150 million in annual savings by 2026. The company raised its full-year 2025 guidance, increasing revenue midpoint by $55 million to $3.13-3.17 billion and adjusted EBITDA midpoint by $25 million to $455-475 million.

Financial highlights include improved adjusted EBITDA of $138 million (26% increase), reduced net loss to $1 million, and strong cash position of $858 million.

Exact Sciences (NASDAQ: EXAS) has expanded its partnership with Humana to provide broader access to colorectal cancer screening through Cologuard Plus™. Starting August 2025, the non-invasive screening test will be available as an in-network service for eligible Humana Medicare Advantage members across the nation.

The partnership targets Humana's 5.8 million Medicare Advantage members, making Cologuard Plus™ more accessible for at-home colorectal cancer screening. The test, which launched in March 2025, has secured FDA approval, Medicare coverage, and inclusion in U.S. Preventive Services Task Force guidelines.

Exact Sciences (NASDAQ: EXAS), a leader in cancer screening and diagnostic tests, has scheduled its second quarter 2025 earnings release for August 6, 2025, after U.S. market close. Management will host a conference call and webcast at 5:00 PM ET on the same day to discuss the company's financial performance and business developments.

The webcast will be accessible through the company's website, with dial-in options available for both domestic (888-330-2384) and international (+1 240-789-2701) participants using access code 4437608. A replay will be made available on the company's website following the live event.